Almirall’s Dermatology Pitch Takes Shape
Executive Summary
CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.
You may also be interested in...
Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent
Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.